3-[3-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol | 1123738-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[3-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
• CAS: 1123738-46-4
• 化学式: C₂₀H₁₉F₃N₄O
• 分子量: 388.392
• InChiKey: QNCYYRHIUFGGJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-chloro-5-bromo-7-trifluoromethylquinoxaline 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 3-[3-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  参考文献：
  名称：

  Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase

  摘要：

  A series of quinoxaline inhibitors of c-Met kinase is described. The postulated binding mode was confirmed by an X-ray crystal structure and optimisation of the series was performed on the basis of this structure. Future directions for development of the series are discussed together with the identification of a novel quinoline scaffold.

  DOI：

  10.1016/j.bmcl.2008.11.062

文献信息

• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• [EN] COMBINATION ANTI-CANCER THERAPY<br/>[FR] POLYTHÉRAPIE ANTINÉOPLASIQUE
  申请人：OSI PHARMACEUTICALS LLC

  公开号：WO2013152252A1

  公开（公告）日：2013-10-10

  The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an inhibitor of MET kinase signaling (e.g. a small molecule MET kinase inhibitor, an anti-MET antibody, or an HGF binding protein) and an inhibitor of IGF-1R signaling (e.g. a small molecule IGF-1R kinase inhibitor (e.g. OSI-906), an anti-IGF-1R antibody, or one or more IGF binding proteins (e.g. IGFBP3)). The present invention also provides a pharmaceutical composition comprising a combination of an inhibitor of MET kinase signaling and an inhibitor of IGF-1R signaling, with a pharmaceutically acceptable carrier. The present invention also provides such methods or compositions where the inhibitory activities of MET kinase signaling and IGF-1R kinase signaling reside in the same molecule.
• Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase
  作者：John Porter、Simon Lumb、Fabien Lecomte、James Reuberson、Anne Foley、Mark Calmiano、Kelly le Riche、Helen Edwards、Jean Delgado、Richard J. Franklin、Jose M. Gascon-Simorte、Alison Maloney、Christoph Meier、Mark Batchelor

  DOI：10.1016/j.bmcl.2008.11.062

  日期：2009.1

  A series of quinoxaline inhibitors of c-Met kinase is described. The postulated binding mode was confirmed by an X-ray crystal structure and optimisation of the series was performed on the basis of this structure. Future directions for development of the series are discussed together with the identification of a novel quinoline scaffold.